リキッドバイオプシー市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年11月

リキッドバイオプシー市場 : 製品(アッセイキット、器具)、循環バイオマーカー(CTC、ctDNA)、テクノロジー(NGS、PCR)、用途(がん(肺、乳房)、非がん)、サンプルタイプ(血液)、エンドユーザー(リファレンスラボ、病院) – 2027 年までの世界予測
Liquid Biopsy Market by Product (Assay Kits, Instruments), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast), Non-Cancer), Sample Type (Blood), End User (Reference Lab, Hospitals) – Global Forecast to 2027

ページ数 263
図表数 258
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The global liquid biopsy market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% during the forecast period.

リキッドバイオプシー市場 : 製品(アッセイキット、器具)、循環バイオマーカー(CTC、ctDNA)、テクノロジー(NGS、PCR)、用途(がん(肺、乳房)、非がん)、サンプルタイプ(血液)、エンドユーザー(リファレンスラボ、病院) - 2027 年までの世界予測

Market growth is driven by factors such as rising global prevalence of cancers and the growing need for early detection coupled with efficient treatment monitoring and recurrence detection is anticipated to support the growth of the global liquid biopsy market. Liquid biopsy also enables the detection of cancer recurrence at earlier than traditional diagnosis methods. Early diagnosis enabled by liquid biopsy tests help healthcare professionals to improve various cancer treatments. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.
“The assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product & service, during the forecast period”
The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. In 2021, the assay kits segment accounted for the highest growth rate in the liquid biopsy market. The accessibility of a wide range of reagents and kits and simple availability to a wide range of assays are the major factors driving the growth of the liquid biopsy assay kits market.
“Non-cancer applications segment accounted for the highest CAGR”
Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2021, the non-cancer application segment accounted for the highest growth rate. This can be attributed to the increasing research activities in NIPT, organ transplant diagnosis and infectious diseases.
“Asia Pacific: The fastest-growing region liquid biopsy market”
The global liquid biopsy market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.
The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas). These factors are expected to provide significant growth opportunities for liquid biopsy companies operating in this region.
The APAC, which is becoming a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure & treatment costs and the availability of highly educated physicians have driven medical tourists to APAC countries. This is a major factor driving the growth of the market in this region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 40%, Tier 2 – 30%, and Tier 3 – 30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%sssss, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Myriad Genetics, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Thermo Fisher Scientific, Inc. (US)
• Guardant Health, Inc. (US)
• MDxHealth SA (Belgium)
• Exact Sciences Corporation (US)
• Illumina Inc. (US)
• Sysmex Inostics (US)
• Bio-Rad Laboratories, Inc. (US)
• Biocept, Inc. (US)
• NeoGenomics, Inc. (US)
• ANGLE plc (UK)
• Menarini-Silicon Biosystems (Italy)
• Vortex Biosciences, Inc. (US)
• Exosome Diagnostics, Inc. (US)
• Agena Bioscience, Inc. (US)
• MedGenome Inc. (US)
• Epigenomics AG (Germany)
• Personal Genome Diagnostics, Inc. (US)

Liquid Biopsy Market by Product (Assay Kits, Instruments), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast), Non-Cancer), Sample Type (Blood), End User (Reference Lab, Hospitals) - Global Forecast to 2027
Research Coverage:
This report provides a detailed picture of the global liquid biopsy market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, clinical application, technology, circulating biomarkers, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.


目次

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.2.1 INCLUSIONS & EXCLUSIONS 35
1.3 STUDY SCOPE 36
1.3.1 LIQUID BIOPSY MARKET 36
1.3.2 REGIONAL SCOPE 37
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY 38
1.5 LIMITATIONS 38
1.6 STAKEHOLDERS 38
1.7 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.2 RESEARCH APPROACH 40
FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY 40
2.2.1 SECONDARY DATA 41
2.2.1.1 Key data from secondary sources 41
2.2.2 PRIMARY DATA 42
2.2.2.1 Primary sources 43
2.2.2.2 Key data from primary sources 43
2.2.2.3 Key industry insights 45
2.2.2.4 Breakdown of primary interviews 45
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 45
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 46
2.3 MARKET SIZE ESTIMATION 46
2.3.1 BOTTOM-UP APPROACH 47
2.3.1.1 Approach 1: Company revenue estimation approach 47
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 47
2.3.1.2 Approach 2: Presentations of companies and primary interviews 47
2.3.1.3 CAGR projections 48
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 48
2.3.2 TOP-DOWN APPROACH 48
FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 7 DATA TRIANGULATION METHODOLOGY 49
2.5 MARKET SHARE 50
2.6 STUDY ASSUMPTIONS 50
2.7 GROWTH RATE ASSUMPTIONS 50
2.8 RISK ASSESSMENT 51
2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET 51
3 EXECUTIVE SUMMARY 52
FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION) 52
FIGURE 9 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022 VS. 2027 (USD MILLION) 53
FIGURE 10 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 54
FIGURE 11 LIQUID BIOPSY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 54
FIGURE 12 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022 VS. 2027 (USD MILLION) 55
FIGURE 13 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION) 55
FIGURE 14 LIQUID BIOPSY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 56
FIGURE 15 LIQUID BIOPSY MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 57
4 PREMIUM INSIGHTS 58
4.1 LIQUID BIOPSY MARKET OVERVIEW 58
FIGURE 16 RISING INCIDENCE OF CANCER TO DRIVE GROWTH IN LIQUID BIOPSY MARKET 58
4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027 58
FIGURE 17 ASSAY KITS TO CONTINUE TO DOMINATE LIQUID BIOPSY MARKET DURING FORECAST PERIOD 58
4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKER, 2022 VS. 2027 59
FIGURE 18 CIRCULATING TUMOR CELLS TO CONTINUE TO DOMINATE MARKET IN 2027 59
4.4 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2022 VS. 2027 59
FIGURE 19 THERAPY SELECTION SEGMENT TO HOLD LARGEST SHARE OF MARKET DURING FORECAST PERIOD 59
4.5 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027 60
FIGURE 20 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO HOLD LARGER SHARE OF MARKET IN 2027 60
4.6 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2022 VS. 2027 60
FIGURE 21 CANCER APPLICATIONS TO LEAD MARKET IN 2027 60
4.7 LIQUID BIOPSY MARKET SHARE, BY SAMPLE TYPE, 2022 VS. 2027 61
FIGURE 22 BLOOD TYPE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027 61
4.8 LIQUID BIOPSY MARKET SHARE, BY END USER, 2022 VS. 2027 61
FIGURE 23 REFERENCE LABORATORIES TO DRIVE MARKET GROWTH IN 2027 61
4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN LIQUID BIOPSY MARKET DURING FORECAST PERIOD 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.2.1 DRIVERS 64
5.2.1.1 Rising incidence and prevalence of cancer 64
TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER 64
5.2.1.2 Cancer awareness initiatives undertaken by global health organizations 65
5.2.1.3 Increasing preference for non-invasive treatment procedures 65
5.2.2 RESTRAINTS 66
5.2.2.1 Lower sensitivity of certain liquid biopsy procedures 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 Growing significance of companion diagnostics 67
5.2.3.2 Growth opportunities in emerging countries 67
5.2.4 CHALLENGES 68
5.2.4.1 Unclear reimbursement scenario 68
5.3 PRICING ANALYSIS 68
TABLE 2 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT 68
TABLE 3 AVERAGE SELLING PRICE TREND 69
5.4 PATENT ANALYSIS 70
FIGURE 26 PATENT ANALYSIS OF LIQUID BIOPSY 70
TABLE 4 PATENT ANALYSIS 71
5.5 VALUE CHAIN ANALYSIS 72
FIGURE 27 MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASE 73
5.6 SUPPLY CHAIN ANALYSIS 73
FIGURE 28 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS 74
5.7 ECOSYSTEM ANALYSIS OF LIQUID BIOPSY MARKET 75
FIGURE 29 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS 75
5.7.1 LIQUID BIOPSY MARKET: ROLE IN ECOSYSTEM 75
5.8 PORTER’S FIVE FORCES ANALYSIS 76
TABLE 5 LIQUID BIOPSY MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.8.1 THREAT FROM NEW ENTRANTS 76
5.8.2 THREAT FROM SUBSTITUTES 76
5.8.3 BARGAINING POWER OF BUYERS 76
5.8.4 BARGAINING POWER OF SUPPLIERS 76
5.8.5 DEGREE OF COMPETITION 77
5.9 REGULATORY LANDSCAPE 77
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
5.9.2 NORTH AMERICA 79
5.9.2.1 US 79
5.9.2.2 Canada 79
5.9.3 EUROPE 79
5.9.4 ASIA PACIFIC 79
5.9.4.1 China 79
5.9.4.2 Japan 80
5.9.5 LATIN AMERICA 80
5.9.5.1 Brazil 80
5.9.5.2 Mexico 80
5.9.6 MIDDLE EAST 80
5.9.7 AFRICA 81
5.10 TECHNOLOGY ANALYSIS 81
5.11 PESTLE ANALYSIS 82
5.12 TRADE ANALYSIS 83
5.12.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 83
5.12.1.1 Export scenario for liquid biopsy 83
TABLE 11 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 83
5.12.1.2 Import scenario for liquid biopsy 83
TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 83
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (TONS) 84
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023 84
TABLE 14 LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 84
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 86
5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS 86
FIGURE 30 REVENUE SHIFT FOR LIQUID BIOPSY MARKET 86
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 87
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES 87
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES 87
5.15.2 BUYING CRITERIA 88
FIGURE 32 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES 88
TABLE 16 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES 88
5.16 CASE STUDY ANALYSIS 88
5.16.1 CASE STUDY 1 88
5.16.2 CASE STUDY 2 89
6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 90
6.1 INTRODUCTION 91
TABLE 17 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 91
6.2 ASSAY KITS 91
6.2.1 RECURRENT REQUIREMENT AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH 91
TABLE 18 KEY PRODUCTS IN ASSAY KITS MARKET 92
TABLE 19 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 92
6.3 INSTRUMENTS 93
6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH 93
TABLE 20 KEY PRODUCTS IN INSTRUMENTS MARKET 94
TABLE 21 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 94
6.4 SERVICES 95
6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH 95
TABLE 22 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 95
7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 96
7.1 INTRODUCTION 97
TABLE 23 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 97
7.2 CIRCULATING TUMOR CELLS (CTC) 97
7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF OVERALL TUMOR BURDEN TO DRIVE DEMAND 97
TABLE 24 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2020–2027 (USD MILLION) 98
7.3 CIRCULATING TUMOR DNA (CTDNA) 98
7.3.1 ABILITY OF CTDNA ANALYSIS TO SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS TO DRIVE MARKET 98
TABLE 25 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020–2027 (USD MILLION) 99
7.4 CELL-FREE DNA (CFDNA) 99
7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH 99
TABLE 26 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2020–2027 (USD MILLION) 100
7.5 EXTRACELLULAR VESICLES (EVS) 100
7.5.1 ABILITY TO REMAIN STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES TO ENSURE CONSISTENT GROWTH IN MARKET 100
TABLE 27 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020–2027 (USD MILLION) 101
7.6 OTHER CIRCULATING BIOMARKERS 101
TABLE 28 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2020–2027 (USD MILLION) 101
8 LIQUID BIOPSY MARKET, BY TECHNOLOGY 102
8.1 INTRODUCTION 103
TABLE 29 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 103
8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS 103
8.2.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO DRIVE GROWTH 103
TABLE 30 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2020–2027 (USD MILLION) 104
8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS 104
8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION 104
TABLE 31 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2020–2027 (USD MILLION) 105
9 LIQUID BIOPSY MARKET, BY APPLICATION 106
9.1 INTRODUCTION 107
TABLE 32 LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
9.2 CANCER APPLICATIONS 107
TABLE 33 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 (MILLION) 108
TABLE 34 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 108
TABLE 35 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 109
9.2.1 LUNG CANCER 109
9.2.1.1 Growing prevalence of lung cancer to propel market growth 109
TABLE 36 GLOBAL LUNG CANCER INCIDENCE, 2020 VS. 2040 110
TABLE 37 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020–2027 (USD MILLION) 110
9.2.2 BREAST CANCER 111
9.2.2.1 Increasing government funding for breast cancer research to spur growth 111
TABLE 38 GLOBAL BREAST CANCER INCIDENCE, 2020 VS. 2040 112
TABLE 39 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020–2027 (USD MILLION) 112
9.2.3 COLORECTAL CANCER 112
9.2.3.1 Rising prevalence of colorectal cancer to propel market 112
TABLE 40 GLOBAL COLORECTAL CANCER INCIDENCE, 2020 VS. 2040 113
TABLE 41 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020–2027 (USD MILLION) 113
9.2.4 PROSTATE CANCER 114
9.2.4.1 Growing number of prostate cancer patients to support market growth 114
TABLE 42 GLOBAL PROSTATE CANCER INCIDENCE, 2020 VS. 2040 114
TABLE 43 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020–2027 (USD MILLION) 115
9.2.5 MELANOMA 115
9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market growth 115
TABLE 44 GLOBAL MELANOMA INCIDENCE, 2020 VS. 2040 116
TABLE 45 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2020–2027 (USD MILLION) 116
9.2.6 OTHER CANCERS 116
TABLE 46 GLOBAL INCIDENCE OF OTHER CANCERS, 2020 117
TABLE 47 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION) 117
9.3 NON-CANCER APPLICATIONS 118
TABLE 48 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 118
TABLE 49 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
9.3.1 NON-INVASIVE PRENATAL TESTING (NIPT) 119
9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive growth 119
TABLE 50 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2020–2027 (USD MILLION) 119
9.3.2 ORGAN TRANSPLANTATIONS 120
9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth 120
TABLE 51 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATIONS, BY REGION, 2020–2027 (USD MILLION) 120
9.3.3 INFECTIOUS DISEASE TESTING 120
9.3.3.1 Potential to reliably identify a wide variety of infections to drive adoption 120
TABLE 52 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020–2027 (USD MILLION) 121
10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION 122
10.1 INTRODUCTION 123
TABLE 53 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 123
10.2 THERAPY SELECTION 123
10.2.1 GROWING PREFERENCE DUE TO NON-INVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE GROWTH 123
TABLE 54 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2020–2027 (USD MILLION) 124
10.3 TREATMENT MONITORING 124
10.3.1 ABILITY TO QUANTITATIVELY CALCULATE CONCENTRATIONS OF CANCER-RELATED MUTATIONS TO FUEL DEMAND 124
TABLE 55 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2020–2027 (USD MILLION) 125
10.4 RECURRENCE MONITORING 125
10.4.1 ABILITY TO DETECT CANCER MUTATIONS THROUGH CTDNA TO DRIVE GROWTH 125
TABLE 56 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2020–2027 (USD MILLION) 126
10.5 EARLY CANCER SCREENING 126
10.5.1 POTENTIAL OF LIQUID BIOPSY TO DETECT CANCER IN EARLY STAGES TO DRIVE MARKET 126
TABLE 57 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2020–2027 (USD MILLION) 127
11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE 128
11.1 INTRODUCTION 129
TABLE 58 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 129
TABLE 59 LIQUID BIOPSY SAMPLES AND APPLICATIONS 129
11.2 BLOOD 130
11.2.1 SIMPLE AND NON-INVASIVE NATURE TO DRIVE MARKET GROWTH 130
TABLE 60 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2020–2027 (USD MILLION) 130
11.3 OTHER SAMPLE TYPES 130
TABLE 61 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2020–2027 (USD MILLION) 131
12 LIQUID BIOPSY MARKET, BY END USER 132
12.1 INTRODUCTION 133
TABLE 62 LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 133
12.2 REFERENCE LABORATORIES 133
12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES TO DRIVE GROWTH 133
TABLE 63 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 134
12.3 HOSPITALS AND PHYSICIAN LABORATORIES 134
12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH 134
TABLE 64 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 135
12.4 ACADEMIC & RESEARCH CENTERS 135
12.4.1 GROWING FOCUS OF RESEARCH FOR DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH 135
TABLE 65 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2020–2027 (USD MILLION) 136
12.5 OTHER END USERS 136
TABLE 66 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 136
13 LIQUID BIOPSY MARKET, BY REGION 137
13.1 INTRODUCTION 138
TABLE 67 LIQUID BIOPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 138
13.2 NORTH AMERICA 138
TABLE 68 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY TYPE OF CANCER, 2020 139
FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT 140
TABLE 69 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 141
TABLE 71 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 141
TABLE 72 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 142
TABLE 73 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 74 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 75 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 143
TABLE 76 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 143
13.2.1 US 143
13.2.1.1 Increasing prevalence of cancer to drive growth 143
TABLE 77 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 144
TABLE 78 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 144
TABLE 79 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 145
TABLE 80 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 81 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 82 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 146
TABLE 83 US: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 146
13.2.2 CANADA 146
13.2.2.1 Availability of various cancer screening programs to drive growth 146
TABLE 84 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 147
TABLE 85 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 148
TABLE 86 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 148
TABLE 87 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 148
TABLE 88 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 149
TABLE 89 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 149
TABLE 90 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 149
13.3 EUROPE 150
TABLE 91 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 92 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 151
TABLE 93 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 151
TABLE 94 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 151
TABLE 95 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 96 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 97 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 152
TABLE 98 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 153
13.3.1 GERMANY 153
13.3.1.1 Favorable government health policies to support market growth 153
TABLE 99 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 154
TABLE 100 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 154
TABLE 101 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 155
TABLE 102 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 155
TABLE 103 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 155
TABLE 104 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 156
TABLE 105 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 156
13.3.2 UK 156
13.3.2.1 Increasing number of diagnostic laboratories to propel market growth 156
TABLE 106 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 157
TABLE 107 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 157
TABLE 108 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 158
TABLE 109 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 110 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 111 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 159
TABLE 112 UK: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 159
13.3.3 FRANCE 159
13.3.3.1 Rising R&D expenditure to drive market growth 159
TABLE 113 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 160
TABLE 114 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 160
TABLE 115 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 160
TABLE 116 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 161
TABLE 117 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 161
TABLE 118 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 161
TABLE 119 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 162
13.3.4 ITALY 162
13.3.4.1 Growing research on discovery of novel circulating cancer biomarkers to drive market growth 162
TABLE 120 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 163
TABLE 121 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 163
TABLE 122 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 164
TABLE 123 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 164
TABLE 124 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 164
TABLE 125 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 165
TABLE 126 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 165
13.3.5 SPAIN 165
13.3.5.1 Growing focus on personalized medicine to support market growth 165
TABLE 127 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 166
TABLE 128 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 166
TABLE 129 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 167
TABLE 130 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 167
TABLE 131 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 167
TABLE 132 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 168
TABLE 133 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 168
13.3.6 REST OF EUROPE 168
TABLE 134 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 169
TABLE 135 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 169
TABLE 136 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 170
TABLE 137 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 170
TABLE 138 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 170
TABLE 139 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 171
TABLE 140 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 171
13.4 ASIA PACIFIC 171
FIGURE 34 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT 172
TABLE 141 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 173
TABLE 142 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 173
TABLE 143 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 174
TABLE 144 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 174
TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 174
TABLE 146 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 147 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 175
TABLE 148 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 175
13.4.1 CHINA 176
13.4.1.1 Growing public access to advanced healthcare facilities to drive market 176
TABLE 149 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 176
TABLE 150 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 176
TABLE 151 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 177
TABLE 152 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 177
TABLE 153 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 177
TABLE 154 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 178
TABLE 155 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 178
13.4.2 JAPAN 178
13.4.2.1 Universal healthcare reimbursement policy to fuel growth 178
TABLE 156 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 179
TABLE 157 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 179
TABLE 158 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 179
TABLE 159 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 160 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 161 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 180
TABLE 162 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 181
13.4.3 INDIA 181
13.4.3.1 Increasing private & public investments in healthcare system to boost market 181
TABLE 163 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 182
TABLE 164 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 182
TABLE 165 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 182
TABLE 166 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 183
TABLE 167 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 183
TABLE 168 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 183
TABLE 169 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 184
13.4.4 REST OF ASIA PACIFIC 184
TABLE 170 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 184
TABLE 171 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 185
TABLE 172 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 185
TABLE 173 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 186
TABLE 174 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 186
TABLE 175 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 186
TABLE 176 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 187
13.5 LATIN AMERICA 187
13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET 187
TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 188
TABLE 178 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 188
TABLE 179 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 189
TABLE 180 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 189
TABLE 181 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 189
TABLE 182 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 190
TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 190
13.6 MIDDLE EAST & AFRICA 190
13.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET GROWTH 190
TABLE 184 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 191
TABLE 185 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020–2027 (USD MILLION) 192
TABLE 186 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 192
TABLE 187 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 193
TABLE 188 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020–2027 (USD MILLION) 193
TABLE 189 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020–2027 (USD MILLION) 193
TABLE 190 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 194
14 COMPETITIVE LANDSCAPE 195
14.1 OVERVIEW 195
14.2 STRATEGIES OF KEY PLAYERS 195
14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET 195
TABLE 191 OVERVIEW OF STRATEGIES DEPLOYED BY KEY LIQUID BIOPSY COMPANIES 195
14.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 197
FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET 197
14.4 MARKET SHARE ANALYSIS 198
14.4.1 LIQUID BIOPSY MARKET 198
FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2021) 198
TABLE 192 LIQUID BIOPSY MARKET SHARE: DEGREE OF COMPETITION 198
14.5 COMPANY EVALUATION QUADRANT 200
14.5.1 LIST OF EVALUATED VENDORS 200
14.5.2 STARS 200
14.5.3 EMERGING LEADERS 200
14.5.4 PERVASIVE PLAYERS 200
14.5.5 PARTICIPANTS 200
FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 201
14.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021) 202
14.6.1 PROGRESSIVE COMPANIES 202
14.6.2 STARTING BLOCKS 202
14.6.3 RESPONSIVE COMPANIES 202
14.6.4 DYNAMIC COMPANIES 202
FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 203
14.7 COMPETITIVE BENCHMARKING 204
14.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 204
FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET 204
TABLE 193 LIQUID BIOPSY MARKET: COMPANY GEOGRAPHICAL FOOTPRINT 204
TABLE 194 LIQUID BIOPSY MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT 204
TABLE 195 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES 205
14.8 COMPETITIVE SCENARIO 205
14.8.1 PRODUCT LAUNCHES & APPROVALS 205
TABLE 196 KEY PRODUCT LAUNCHES & APPROVALS 205
14.8.2 DEALS 206
TABLE 197 KEY DEALS 206
15 COMPANY PROFILES 208
(Business overview, Products offered, Recent Developments, MNM view)*
15.1 KEY PLAYERS 208
15.1.1 QIAGEN N.V. 208
TABLE 198 QIAGEN N.V.: BUSINESS OVERVIEW 208
FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 209
15.1.2 F. HOFFMANN-LA ROCHE AG 212
TABLE 199 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 212
FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 213
15.1.3 MYRIAD GENETICS, INC. 216
TABLE 200 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW 216
FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021) 217
15.1.4 THERMO FISHER SCIENTIFIC, INC. 221
TABLE 201 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 221
FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 222
15.1.5 GUARDANT HEALTH, INC. 225
TABLE 202 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW 225
FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021) 226
15.1.6 BIO-RAD LABORATORIES, INC. 230
TABLE 203 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 230
FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 231
15.1.7 ILLUMINA, INC. 233
TABLE 204 ILLUMINA, INC.: BUSINESS OVERVIEW 233
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 234
15.1.8 EXACT SCIENCES CORPORATION 236
TABLE 205 EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW 236
FIGURE 47 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2021) 237
15.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION) 239
TABLE 206 SYSMEX INOSTICS: BUSINESS OVERVIEW 239
FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021) 239
15.1.10 BIOCEPT, INC. 241
TABLE 207 BIOCEPT, INC.: BUSINESS OVERVIEW 241
FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2021) 241
15.1.11 MDXHEALTH 244
TABLE 208 MDXHEALTH: BUSINESS OVERVIEW 244
FIGURE 50 MDXHEALTH: COMPANY SNAPSHOT (2021) 244
15.2 OTHER PLAYERS 246
15.2.1 NEOGENOMICS, INC. 246
15.2.2 EPIGENOMICS AG 248
15.2.3 ANGLE PLC 249
15.2.4 MENARINI-SILICON BIOSYSTEMS 251
15.2.5 VORTEX BIOSCIENCES, INC. 253
15.2.6 EXOSOME DIAGNOSTICS, INC. 254
15.2.7 MEDGENOME INC. 255
15.2.8 AGENA BIOSCIENCE, INC. 256
15.2.9 PERSONAL GENOME DIAGNOSTICS, INC. 258
15.2.10 FREENOME HOLDINGS, INC. 260
15.2.11 STRAND LIFE SCIENCES 260
15.2.12 LUNGLIFE AI, INC. 261
15.2.13 LUCENCE HEALTH INC. 261
15.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD. 262
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
16 APPENDIX 263
16.1 DISCUSSION GUIDE 263
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 268
16.3 CUSTOMIZATION OPTIONS 270
16.4 RELATED REPORTS 270
16.5 AUTHOR DETAILS 271


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com